The risk of malignancy among biologic-naïve pediatric psoriasis patients: A retrospective cohort study in a US claims database - 14/12/17
, Beth L. Nordstrom, PhDAbstract |
Background |
Little published literature exists regarding malignancy risk in pediatric psoriasis patients.
Objective |
To compare malignancy risk in biologic-naïve pediatric psoriasis patients with a matched pediatric population without psoriasis.
Methods |
This retrospective cohort study used IMS LifeLink Health Plan Claims data covering 1998-2008. Cancer incidence was compared with the US Surveillance, Epidemiology, and End Results (SEER) data using standardized incidence ratios (SIR), and between cohorts using Cox models.
Results |
Among 9045 pediatric psoriasis patients and 77,206 comparators, 18 probable or highly probable cancers were identified. Pediatric psoriasis patients had a nonsignificantly lower incidence than comparators (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.05-3.54). The HR increased to 1.67 (95% CI 0.54-5.18) when cancer diagnosed during the first 90 days of follow-up was included. The pediatric psoriasis cohort had a significantly increased lymphoma rate compared with SEER (SIR 5.42, 95% CI 1.62-12.94), but no significant increase relative to the comparator cohort.
Limitations |
Misclassification of disease and outcome might have occurred with patients in the claims database.
Conclusion |
Patients with pediatric psoriasis showed no significant increase in overall cancer risk compared with those without psoriasis. A potential increased risk for lymphoma was observed when compared with the general population.
Le texte complet de cet article est disponible en PDF.Key words : cancer, cohort study, epidemiology, incidence rates, lymphoma, pediatric psoriasis
Abbreviations used : CI, EM, HR, ICD-9, NMSC, PUVA, PYs, SEER, SIR, TNF
Plan
| Funding sources: Supported by Pfizer Inc. |
|
| Conflicts of interest: Dr Gu is employed by Pfizer and owns stock and stock options in Pfizer. Dr Nordstrom is employed by Evidera, which received funding from Pfizer for the study and the development of the manuscript. |
|
| Reprints not available from the authors. |
Vol 77 - N° 2
P. 293 - août 2017 Retour au numéro
Article précédent
- Real-world burden of comorbidities in US patients with psoriasis
- Kamal Shah, Lillian Mellars, Arun Changolkar, Steven R. Feldman
- Herpes zoster in psoriasis patients treated with tofacitinib
- Kevin L. Winthrop, Mark Lebwohl, Arnon D. Cohen, Jeffrey M. Weinberg, Stephen K. Tyring, Scott T. Rottinghaus, Pankaj Gupta, Kaori Ito, Huaming Tan, Mandeep Kaur, Alexander Egeberg, Lotus Mallbris, Hernan Valdez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?